|
|
|
|
|
Epoetin alfa
drug data and news
Epoetin alfa drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Epoetin alfa | ||
| Brand Names/Synonyms | Erythropoietin precursor;Epoetin; Epogen (Amgen Inc.); Epogin (Chugai); Epomax (Elanex); Eprex (Janssen-Cilag. Ortho Biologics LLC); NeoRecormon (Roche); Recormon (Roche); Procrit (Ortho Biotech) | ||
| Indication | For treatment of anemia (from renal transplants or certain HIV treatment) | ||
| Sponsored links | Description | Human erythropoietin (recombinant), produced by CHO cells. | |
| Pharmacology | Used in the treatment of anemia. Involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass. | ||
| Mechanism Of Action | Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation. | ||
| Epoetin alfa News (When available) |
DG News ATLANTA, GA -- December 14, 2005 -- Epoetin alfa (Procrit) 80,000 units administered every three weeks to patients on an every three-week chemotherapy regimen ... Updated Interim Aranesp(R) Phase 2 Data Suggest Major Response in ... Dec 11, 2005 Business Wire (press release), Amgen revolutionized anemia treatment with the development of recombinant erythropoietin, Epoetin alfa. Building on this heritage ... Epogen: reports of pure red cell aplasia and severe anemia ... Dec 11, 2005 Xagena.it, Amgen and FDA notified HealthCare Professionals of revision to sections of the prescribing information for Epogen ((Epoetin alfa ). ... Higher doses of pegylated interferon or ribavirin improve ... Dec 8, 2005 Aidsmap, ...of chronic Hepatitis C virus (HCV) genotype 1 with peginterferon alfa-2b (PEGIFN), high weight based dose ribavirin (RVN) and Epoetin alfa (EPO) enhances ... Aranesp® Effective in Low and Intermediate Risk Myelodysplastic ... Dec 7, 2005 Cancer Consultants (press release), Researchers from Italy have demonstrated that long-acting Aranesp (darbepoetin alfa) is as effective as Procrit® (epoetin alfa) for the treatment of patients ... Zacks.com announces that Richard Moroney highlights the following ... Dec 15, 2005 Business Wire (press release), They manufacture and market four human therapeutic products, EPOGEN(R) (Epoetin alfa), NEUPOGEN(R) (Filgrastim), INFERGEN(R) (Interferon alfacon-1) and STEMGEN ... b>May 4, 2006 ...friendly therapy option for anaemia, which is currently treated with injectable recombinant forms of EPO such as Amgen's Epogen (epoetin alfa) and Aranesp ... - Pharma Times (subscription), Data From Correction of Hemoglobin and Outcomes in Renal ... Apr 20, 2006 Amgen's First Quarter 2006 Adjusted Earnings per Share, Excluding ... Apr 20, 2006 Dose-Dense R-CHOP-14 Can Be Safely Administered to NHL Patients ... Apr 25, 2006 Source: Rockwell Medical Technologies, Inc. Apr 20, 2006 Fibrogen, Astellas Anemia Deal: $300M, Plus $465M In Milestones Apr 28, 2006 | ||
| Dosage Forms | SOLUTION | ||
| Drug_Category | Antianemic Agents; hematopoietic agents (20:16.00) | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Human erythropoietin | ||
| Chemical Formula | C815H1317N233O241S5 | ||
| Molecular Weight | 18396.1 | ||
| Smiles String | Not Available | ||
| Melting Point | 53 oC (Arakawa, T. et al., Biosci. Biotechnol. Biochem. 65:1321-1327 (2001)). | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | Not Available | ||
| Isoelectric Point | 8.75 | ||
| Biotransformation | Not Available | ||
| Half Life | Not Available | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.rxlist.com/cgi/generic/epoetin.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00103 | ||
| CAS Registry Number | 11096-26-7 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | PA449478 | ||
| SwissProt ID | EPO_HUMAN (P01588) | ||
| GenBank ID | X02158 | ||
| Drug ID Number [DIN] | 2243403 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |